Anaplastic
Large Cell
Related Abstracts:
Adult
PubMed
Childhood
PubMed
T/null cell, primary cutaneous or systemic
PubMed
|
Investigational treatments for:
|
AIDS/HIV -related
Related Abstracts:
PubMed
|
Investigational treatments for:
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
|
Related Abstracts:
PubMed
|
Investigational
treatments for:
|
|
Related Abstracts:
PubMed
ASH 2009
|
Investigational treatments (updated Jan
2010)
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
|
|
Related Abstracts:
PubMed
ASCO
Medscape
|
Investigational treatments for:
|
|
Related Abstracts:
PubMed
ASCO
Medscape
ASH 2009
|
Investigational treatments for:
|
|
Related Abstracts:
PubMed
|
Investigational
treatments for:
|
|
Related Abstracts:
PubMed
|
Investigational
treatments for:
|
|
Related Abstracts:
PubMed
|
Investigational
treatments for:
|
|
Related Abstracts:
PubMed
Medscape
|
Investigational
treatments for:
|
MDS
Myelodysplastic Syndrome
Related Abstracts:
PubMed
ASCO
Medscape
|
Investigational
treatments for:
 |
MDS
(Myelodysplastic Syndrome) -
a complication of treatment for lymphoma
|
|
|
Related Abstracts:
ASH 2009
|
Investigational treatments for:
|
|
Related Abstracts:
PubMed
|
Investigational treatments for:
By Subtype (by request):
By investigational agents:
|
Anti-Tac
for Tac-expressing NHL, including T-cell NHL)
|
| Daclizumab
(t-cell lymphomas) |
| Denileukin
diftitox - ONTAK
(IL-2/diphtheria toxin fusion protein)
Possible mechanisms: "The IL-2 portion of the molecule
targets the lymphoma cells by binding to the IL-2 receptor on the
plasma membrane, and upon endocytosis, the diphtheria toxin is
delivered to the lymphoma cells. Common side effects are nausea
and vomiting, fever and flu-like symptoms. Other significant side
effects include the cytokine release syndrome and vascular leak
syndrome"- ncbi.nlm.nih.gov/books
 Topic Search on this
agent: PubMed
|
| Depsipeptide
(histone deacetylase inhibitor)
Possible mechanisms: induction of apoptosis, cell cycle arrest,
and differentiation via the modulation of gene expression by
histone acetylation
Topic Search on this
agent: PubMed
|
|
|
| Pralatrexate
Possible mechanisms: "Pralatrexate is a novel antifolate
designed to have high affinity for the reduced folate carrier type
1 (RFC-1). Preclinical and clinical studies have demonstrated that
pralatrexate has significant activity against TCL." - PMID:
16988580
Topic Search on this
agent: PubMed
|
|
|
| SAHA
(Suberoylanilide Hydroxamic Acid)
Possible mechanisms: "SAHA treatment caused an
accumulation of acetylated histones (H2B, H3, and H4), an increase
of p21(WAF1) and bax proteins, a decrease of Stat6 and
phospho-Stat6 proteins, and activation of caspase-3 in CTCL cells."
- PMID:
16297208
Topic Search on this
agent: PubMed
|
| T-cell
antibodies (biological agents that bind to receptors
expressed on t-cells)
|
|
|
|
Investigational
treatments for indolent lymphomas
transformed to aggressive:
|
|
| CLL
(transformed Chronic Lymphocytic Lymphoma/Leukemia)
|
|
|
|
|
|
|
Related Abstracts:
PubMed
|
Investigational
treatments for:
|
